

Aaron R Hansen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3527322/aaron-r-hansen-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

195
papers

8,227
citations

38
h-index

89
g-index

222
ext. papers

11,263
ext. citations

4.8
avg, IF

6.19
L-index

#	Paper	IF	Citations
195	Risk Stratification of HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Are All Tumors Created Equally?. <i>Current Otorhinolaryngology Reports</i> , 2022 , 10, 68	0.5	
194	Unfinished Business in Classifying HPV-Positive Oropharyngeal Carcinoma: Identifying the Bad Apples in a Good Staging Barrel.. <i>Oncologist</i> , 2022 , 27, 4-6	5.7	0
193	Inter-rater concordance and operating definitions of radiologic nodal feature assessment in human papillomavirus-positive oropharyngeal carcinoma.. <i>Oral Oncology</i> , 2022 , 125, 105716	4.4	1
192	Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101874	2.2	27
191	Comparison of patients with high-risk nonmetastatic clear cell renal carcinoma in adjuvant therapy trials versus nonclinical trial patients.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 361-361	2.2	
190	The survival outcomes of the metastatic renal cell carcinoma with rhabdoid differentiation in immunotherapy era: Princess Margaret Cancer Center experience.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 333-333	2.2	
189	Association of cabozantinib dose reductions for toxicity with clinical effectiveness in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 316-316	2.2	
188	Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 346-346	2.2	
187	Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 304-304	2.2	
186	Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 224-224	2.2	1
185	Genomic characterization and identification of actionable variants in patients with locally advanced or metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 562-562	2.2	
184	The role of cytoreductive nephrectomy and systemic therapy in the management of tumor thrombus in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 345-345 ^{2,2}		
183	Daily symptom monitoring commonly leads to treatment modification in older adults receiving treatment for metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 82-82	2.2	1
182	Survival outcomes of metastatic renal cell carcinoma (mRCC) with sarcomatoid differentiation (SD): A single-institutional experience and literature meta-analysis.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 332-332	2.2	
181	Radiologic-pathologic correlation of major versus minor extranodal extension in oral cavity cancer.. <i>Head and Neck</i> , 2022 ,	4.2	1
180	Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts. <i>International Journal of Cancer</i> , 2021 ,	7.5	1
179	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. <i>PLoS ONE</i> , 2021 , 16, e0259272	3.7	0

178	Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers. <i>Cancer</i> , 2021 ,	6.4	1
177	Prognostic importance of radiologic extranodal extension in nasopharyngeal carcinoma treated in a Canadian cohort. <i>Radiotherapy and Oncology</i> , 2021 , 165, 94-102	5.3	2
176	Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa115	4.6	3
175	Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies. <i>Cancer</i> , 2021 , 127, 1360-1368	6.4	2
174	Assessment Criteria and Clinical Implications of Extranodal Extension in Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021 , 41, 265-278	7.1	6
173	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2021 , 15, 84-97	1.2	1
172	Real-World Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , 2021 , 5, 21-29	0.6	0
171	Pathologic concordance of resected metastatic nonseminomatous germ cell tumors in the chest. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 161, 856-868.e1	1.5	3
170	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	4
169	Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapy. <i>Radiotherapy and Oncology</i> , 2021 , 157, 255-262	5.3	1
168	Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021 , 127, 2587-2594	6.4	4
167	Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab β bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).. <i>Journal of Clinical Oncology</i> , 2021 39, 1553-1562	2.2	0
166	Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6081-6081	2.2	0
165	Preliminary results of BEAVER: An investigator-initiated phase II study of binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e15038-e15038	2.2	0
164	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1553-1562	2.2	13
163	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1563-1574	2.2	19
162	Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review. <i>Cancer Medicine</i> , 2021 , 10, 5031-5040	4.8	2
161	Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021 , 4, e2114694	10.4	2

160	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , 2021 , 10, 5775-5782	4.8	2
159	Pre- and Post-Radiotherapy Radiologic Nodal Features and Oropharyngeal Cancer Outcomes. <i>Laryngoscope</i> , 2021 , 131, E1162-E1171	3.6	5
158	Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. <i>European Urology Oncology</i> , 2021 , 4, 483-491	6.7	11
157	Significantly Minimizing Drug Wastage and the Cost of Cabazitaxel Used to Treat Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021 , 79, 177-179	10.2	0
156	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021 , 4, 102-111	6.7	15
155	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021 , 4, e2021869	10.4	23
154	Underreporting of Symptomatic Adverse Events in Phase I Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 980-988	9.7	7
153	Prognostic value of clinical and radiologic extranodal extension and their role in the 8th edition TNM cN classification for HPV-negative oropharyngeal carcinoma. <i>Oral Oncology</i> , 2021 , 114, 105167	4.4	6
152	Construct Validity of the EuroQoL-5 Dimension and the Health Utilities Index in Head and Neck Cancer. <i>Otolaryngology - Head and Neck Surgery</i> , 2021 , 1945998211030173	5.5	0
151	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 354-361	3.3	1
150	Out-of-pocket costs associated with head and neck cancer treatment. <i>Cancer Reports</i> , 2021 , e1528	1.5	1
149	Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study 2021 , 9,		4
148	Contemporary Opportunities in Nonsurgical Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma 2021 , 119-137		
147	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021 , 10, 1212-1221	4.8	4
146	Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer.. <i>Cancer Medicine</i> , 2021 ,	4.8	1
145	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , 2020 , 147, 2190-2198	7.5	107
144	Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1753-1768	3.8	2
143	Use of combined androgen deprivation therapy with postoperative radiation treatment for prostate cancer: Impact of randomized trials on clinical practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 848.e1-848.e7	2.8	3

142	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , 2020 , 108, 104736	4.4	23
141	Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal. <i>Cancer</i> , 2020 , 126, 3426-3437	6.4	19
140	Controversies in the management of clinical stage 1 testis cancer. <i>Canadian Urological Association Journal</i> , 2020 , 14, E537-E542	1.2	0
139	Treatment implications of postoperative chemoradiotherapy for squamous cell carcinoma of the oral cavity with minor and major extranodal extension. <i>Oral Oncology</i> , 2020 , 110, 104845	4.4	10
138	Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire. <i>Cancer</i> , 2020 , 126, 4042-4050	6.4	12
137	Cancer patients' experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , 2020 , 9, 3015-3022	4.8	6
136	Durable therapeutic gain despite competing mortality in long-term follow-up of a randomized hyperfractionated radiotherapy trial for locally advanced head and neck cancer. <i>Clinical and Translational Radiation Oncology</i> , 2020 , 21, 69-76	4.6	1
135	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. <i>Oncologist</i> , 2020 , 25, 422-430	5.7	5
134	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , 2020 , 105, 104666	4.4	3
133	Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer. <i>Head and Neck</i> , 2020 , 42, 2277-2286	4.2	6
132	First-in-class microbial ecosystem therapeutics 4 (MET4) in metastatic solid cancer patients treated with immunotherapy: MET4-IO.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3098-3098	2.2	3
131	Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5063-5063	2.2	3
130	Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5071-5071	2.2	2
129	Recurrent or metastatic salivary gland tumor (MSGT) patients treated with selinexor, a first in class selective exportin-1 (XPO1) inhibitor.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 6586-6586	2.2	1
128	Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry. <i>F1000Research</i> , 2020 , 9, 337	3.6	2
127	Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 642-642	2.2	3
126	Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 684-684	2.2	2
125	Development of a Functional Assessment of Chronic Illness Therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators. <i>Journal of Cancer Metastasis and Treatment</i> , 2020 , 6,	3.8	2

124	Barriers and facilitators to implementation of serial point-of-care hearing tests using a novel iPad-based audiometry in platinum chemotherapy-treated cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 223-223	2.2	
123	An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 283-283	2.2	
122	An evaluation of administrative data linkage for measurement of real-world outcomes of large clinical panel sequencing for advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19303-e19303	2.2	
121	Persistence of platinum in semen of cisplatin-treated survivors of advanced testicular cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5056-5056	2.2	
120	Mapping PRO-CTCAE responses to clinician-graded adverse events, dose reductions, interruptions, and discontinuations in phase I cancer trials.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2014-2014	2.2	1
119	Characterization and outcomes of patients enrolled to multiple phase I cancer trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 85, 469-472	3.5	
118	Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1-10	2.2	786
117	Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification. <i>Radiotherapy and Oncology</i> , 2020 , 144, 13-22	5.3	17
116	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020 , 126, 1550-1558	6.4	9
115	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e350-e359	3.3	1
114	Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancer. <i>Head and Neck</i> , 2020 , 42, 513-521	4.2	6
113	Dual Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancer: Just a Gambit or Real CheckMate?. <i>Cancer Cell</i> , 2020 , 38, 438-440	24.3	2
112	Systematic Review and STARD Scoring of Renal Cell Carcinoma Circulating Diagnostic Biomarker Manuscripts. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa050	4.6	0
111	Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis. <i>Urology</i> , 2020 , 138, 69-76	1.6	2
110	A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. <i>Clinical and Translational Science</i> , 2020 , 13, 1178-1188	4.9	9
109	Multiple imputation and clinico-serological models to predict human papillomavirus status in oropharyngeal carcinoma: An alternative when tissue is unavailable. <i>International Journal of Cancer</i> , 2020 , 146, 2166-2174	7.5	6
108	Advanced Adrenocortical Carcinoma (ACC): a Review with Focus on Second-Line Therapies. <i>Hormones and Cancer</i> , 2020 , 11, 155-169	5	9
107	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019 , 76, 861-867	10.2	39

106	Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy. <i>Oral Oncology</i> , 2019 , 97, 124-130	4.4	2
105	Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region. <i>International Journal of Cancer</i> , 2019 , 145, 1465-1474	7.5	15
104	The microbiome and cancer for clinicians. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 141, 1-12	7	50
103	Computer-assisted image analysis of the tumor microenvironment on an oral tongue squamous cell carcinoma tissue microarray. <i>Clinical and Translational Radiation Oncology</i> , 2019 , 17, 32-39	4.6	10
102	Radiologic Extranodal Extension Portends Worse Outcome in cN+ TNM-8 Stage I Human Papillomavirus-Mediated Oropharyngeal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 1017-1027	4	38
101	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. <i>British Journal of Cancer</i> , 2019 , 120, 1113-1119	8.7	42
100	Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1919-1926	2.2	29
99	An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) 2019 , 7, 72		16
98	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , 2019 , 24, 1188-1194	5.7	17
97	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2019 , 68, 773-785	7.4	53
96	Biomarkers in Non-Schistosomiasis-related squamous cell carcinoma of the urinary bladder: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 135, 76-84	7	5
95	Postoperative wound infections, neutrophil-to-lymphocyte ratio, and cancer recurrence in patients with oral cavity cancer undergoing surgical resection. <i>Oral Oncology</i> , 2019 , 97, 23-30	4.4	7
94	HPV Status Improves Classification of Head and Neck Gray Zone Cancers. <i>Journal of Dental Research</i> , 2019 , 98, 879-887	8.1	3
93	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2019 , 118, 112-120	7.5	5
92	Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer Patients Using Nanoparticle-Mediated Ranking. <i>Analytical Chemistry</i> , 2019 , 91, 9348-9355	7.8	18
91	Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option. <i>European Urology Focus</i> , 2019 , 5, 702-703	5.1	3
90	Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts. <i>PLoS ONE</i> , 2019 , 14, e0222359	3.7	4
89	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019 , 394, 1915-1928	40	839

88	Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma. <i>European Journal of Cancer</i> , 2019 , 123, 138-145	7.5	9
87	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz071	4.6	2
86	Role of the oral and gut microbiota as a biomarker in locoregionally advanced oropharyngeal squamous cell carcinoma (ROMA LA-OPSCC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6045-6045	2.2	3
85	Structure and Optimization of Checkpoint Inhibitors. <i>Cancers</i> , 2019 , 12,	6.6	27
84	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019 , 125, 1341-1349	6.4	78
83	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , 2019 , 24, e518-e525	5.7	
82	Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library. <i>Oncologist</i> , 2019 , 24, e146-e148	5.7	14
81	Finding/identifying primaries with neck disease (FIND) clinical trial protocol: a study integrating transoral robotic surgery, histopathological localisation and tailored deintensification of radiotherapy for unknown primary and small oropharyngeal head and neck squamous cell carcinoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6045-6045	3	5
80	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019 , 2, 643-648	6.7	19
79	Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours. <i>European Urology Oncology</i> , 2019 , 2, 437-442	6.7	8
78	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , 2019 , 108, 69-77	7.5	20
77	Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 1107-1116	4	30
76	Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. <i>Journal of Urology</i> , 2018 , 200, 126-135	2.5	65
75	Partial Laryngeal IMRT for T2N0 Glottic Cancer: Impact of Image Guidance and Radiation Therapy Intensification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 941-949	4	14
74	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky021	4.6	73
73	Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. <i>Cancer Research</i> , 2018 , 78, 5398-5407 ^{10.1}		15
72	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. <i>Annals of Oncology</i> , 2018 , 29, 1807-1813	10.3	165
71	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. <i>BJU International</i> , 2018 , 122, 814-822	5.6	3

70	Surgery- vs Radiation-Based Therapy for p16+/HPV-Related Oropharyngeal Cancers. <i>Current Otorhinolaryngology Reports</i> , 2018 , 6, 298-309	0.5	3
69	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. <i>Canadian Urological Association Journal</i> , 2018 , 12, 59-66	1.2	8
68	A New Staging System for HPV-Related Oropharynx Cancer: Rationale, Derivation, Validation and Practical Applications 2018 , 149-164		1
67	Human Papillomavirus and Head and Neck Cancer 2018 , 167-181		
66	The Current State of Biological and Clinical Implications of Human Papillomavirus-Related Oropharyngeal Cancer. <i>Seminars in Radiation Oncology</i> , 2018 , 28, 17-26	5.5	13
65	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-12	5.2	10
64	Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. <i>Annals of Oncology</i> , 2018 , 29, viii315	10.3	2
63	Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-20	3.6	
62	The interplay of IMRT and transoral surgery in HPV-mediated oropharyngeal cancer: Getting the balance right. <i>Oral Oncology</i> , 2018 , 86, 171-180	4.4	12
61	Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma. <i>Cell Reports</i> , 2018 , 25, 1318-1331.e4	10.6	41
60	First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1. <i>Annals of Oncology</i> , 2018 , 29, viii404	10.3	3
59	Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 340-352	4	64
58	Radiologic-Pathologic Correlation of Extranodal Extension in Patients With Squamous Cell Carcinoma of the Oral Cavity: Implications for Future Editions of the TNM Classification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 698-708	4	34
57	Effect of Intensity Modulated Radiation Therapy With Concurrent Chemotherapy on Survival for Patients With Cervical Esophageal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 186-195	4	16
56	Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25 Years Later. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 159-169	4	41
55	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017 , 54, 43-57	14.4	11
54	A comprehensive review of immunotherapies in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 113, 292-303	7	43
53	Determinants of the recommended phase 2 dose of molecular targeted agents. <i>Cancer</i> , 2017 , 123, 1409-1415	4.15	4

52	Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 858-867	4	13
51	Morphologic and topographic radiologic features of human papillomavirus-related and -unrelated oropharyngeal carcinoma. <i>Head and Neck</i> , 2017 , 39, 1524-1534	4.2	23
50	Overview of the 8th Edition TNM Classification for Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 40	5.4	261
49	Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity-modulated radiotherapy. <i>Cancer</i> , 2017 , 123, 3691-3700	6.4	57
48	Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review. <i>British Journal of Cancer</i> , 2017 , 117, 1743-1752	8.7	38
47	Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4050-4056	2.2	211
46	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. <i>Annals of Oncology</i> , 2017 , 28, 2377-2385	10.3	372
45	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. <i>European Urology</i> , 2017 , 71, 120-127	10.2	34
44	Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking. <i>Nature Nanotechnology</i> , 2017 , 12, 274-281	28.7	149
43	Cost-Effectiveness Analysis of Radiation Therapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 709-717	4	25
42	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. <i>Oncotarget</i> , 2017 , 8, 32918-32929	3.3	30
41	Treatment of Viral-Associated HNC (OPC and NPC) 2017 , 177-188		
40	A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. <i>Genetics in Medicine</i> , 2016 , 18, 128-36	8.1	66
39	A comparison of weekly versus 3-weekly cisplatin during adjuvant radiotherapy for high-risk head and neck cancer. <i>Oral Oncology</i> , 2016 , 59, 43-49	4.4	12
38	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , 2016 , 30, 571-584	7.9	66
37	Radiotherapy Characteristics and Outcomes for Head and Neck Carcinoma of Unknown Primary vs T1 Base-of-Tongue Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016 , 142, 1208-1215	3.9	15
36	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016 , 8, 109	14.4	149
35	Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016 , 12, e222-8	1.9	6

34	Outcomes and prognostic factors for major salivary gland carcinoma following postoperative radiotherapy. <i>Oral Oncology</i> , 2016 , 54, 75-80	4.4	32
33	Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 858-67	12.9	13
32	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. <i>Lancet Oncology, The</i> , 2016 , 17, 440-451	21.7	448
31	PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development. <i>JAMA Oncology</i> , 2016 , 2, 15-6	13.4	84
30	Phase I Study Methodology in Head and Neck Oncology 2016 , 731-742		
29	Hypopharyngeal cancer: looking back, moving forward. <i>Current Oncology</i> , 2016 , 23, 221-2	2.8	9
28	Challenges in establishing the diagnosis of human papillomavirus-related oropharyngeal carcinoma. <i>Laryngoscope</i> , 2016 , 126, 2270-5	3.6	24
27	Impact of p16 expression, nodal status, and smoking on oncologic outcomes of patients with head and neck unknown primary squamous cell carcinoma. <i>Head and Neck</i> , 2016 , 38, 1347-53	4.2	24
26	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). <i>Investigational New Drugs</i> , 2016 , 34, 575-83	4.3	6
25	Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016 , 67, 174-182	7.5	46
24	Early phase clinical trials to identify optimal dosing and safety. <i>Molecular Oncology</i> , 2015 , 9, 997-1007	7.9	59
23	Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. <i>Journal of Clinical Oncology</i> , 2015 , 33, 836-45	2.2	279
22	A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2015 , 26, 1824-1829	10.3	139
21	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials. <i>Oncologist</i> , 2015 , 20, 653-9	5.7	18
20	Mitosis trumps T stage and proposed international association for the study of lung cancer/american thoracic society/european respiratory society classification for prognostic value in resected stage 1 lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 673-81	8.9	25
19	Primary surgery versus (chemo)radiotherapy in oropharyngeal cancer: the radiation oncologist@ and medical oncologist@ perspectives. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2015 , 23, 139-47	2	20
18	Reply to J.J. Beitler et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3218-9	2.2	1
17	Comparison of Health State Utility Measures in Patients With Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015 , 141, 696-703	3.9	34

16	A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers. <i>Clinical Cancer Research</i> , 2015 , 21, 258-66	12.9	24
15	Phase 1 trial design: is 3 + 3 the best?. <i>Cancer Control</i> , 2014 , 21, 200-8	2.2	47
14	A systematic review of immune-related adverse event (irAE) reporting in clinical trials of immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3057-3057	2.2	1
13	Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013 , 87, 1078-85	4	79
12	The changing incidence of human papillomavirus-associated oropharyngeal cancer using multiple imputation from 2000 to 2010 at a Comprehensive Cancer Centre. <i>Cancer Epidemiology</i> , 2013 , 37, 820-9	2.8	35
11	Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. <i>Oral Oncology</i> , 2013 , 49, 79-85	4.4	193
10	Tumour heterogeneity in the clinic. <i>Nature</i> , 2013 , 501, 355-64	50.4	770
9	Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 543-50	2.2	454
8	Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. <i>Breast Cancer Research</i> , 2013 , 15, R97	8.3	13
7	Princess Margaret Cancer Centre (PMCC) Integrated Molecular Profiling in Advanced Cancers Trial (IMPACT) using genotyping and targeted next-generation sequencing (NGS).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 11002-11002	2.2	8
6	A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6045-6045	2.2	8
5	Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, 276-83	4	171
4	Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. <i>Radiotherapy and Oncology</i> , 2012 , 103, 49-56	5.3	142
3	Salvage chemotherapy for metastatic germ cell tumours: The known unknowns. <i>Canadian Urological Association Journal</i> , 2012 , 6, 117-8	1.2	
2	Point-of-care outcome assessment in the cancer clinic: audit of data quality. <i>Radiotherapy and Oncology</i> , 2010 , 95, 339-43	5.3	89
1	Principles of cancer staging ³⁴⁻³⁹		4